Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis

Luigi Fedele, Stefano Bianchi, Ricciarda Raffaelli, Giovanni Zanconato

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Study objective: To compare the effect of HRT with transdermal estradiol and that of treatment with tibolone in post-menopausal women with residual endometriosis. Materials and Methods: 21 women with residual pelvic endometriosis after bilateral oophorectomy with or without hysterectomy were enrolled in the study and were randomized to HRT with transdermal estradiol 50 mg twice weekly (n=10) associated with cyclic medroxyprogesterone acetate 10 mg daily in women who preserved uterus, and to treatment with tibolone 2.5 mg administered orally once a day (n=11). The duration of both treatments was scheduled to last at least 12 months. Residual endometriosis was located in the bowel wall in four patients, in the rectovaginal septum in six and deeply in the retroperitoneal pelvic space in six. All women were symptomatic before oophorectomy. Results: All the women were followed for 12 months. No patient suspended therapy because of side effects. Four patients of the estradiol group experienced moderate pelvic pain during treatment compared with only one patient in the tibolone group. One patient in the estradiol group reported severe dyspareunia. Conclusion: Although our series is very small, it seems that tibolone may be a safe hormonal treatment for post-menopausal women with residual endometriosis. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalMaturitas
Volume32
Issue number3
DOIs
Publication statusPublished - Aug 16 1999

Fingerprint

tibolone
Endometriosis
Estradiol
Ovariectomy
Medroxyprogesterone Acetate
Therapeutics
Retroperitoneal Space
Dyspareunia
Pelvic Pain
Hysterectomy
Uterus

Keywords

  • Endometriosis
  • Estrogens
  • Menopause
  • Tibolone

ASJC Scopus subject areas

  • Ageing
  • Obstetrics and Gynaecology

Cite this

Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. / Fedele, Luigi; Bianchi, Stefano; Raffaelli, Ricciarda; Zanconato, Giovanni.

In: Maturitas, Vol. 32, No. 3, 16.08.1999, p. 189-193.

Research output: Contribution to journalArticle

Fedele, Luigi ; Bianchi, Stefano ; Raffaelli, Ricciarda ; Zanconato, Giovanni. / Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. In: Maturitas. 1999 ; Vol. 32, No. 3. pp. 189-193.
@article{7bf1eab46aed4cc0a9a4aa05de8bf525,
title = "Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis",
abstract = "Study objective: To compare the effect of HRT with transdermal estradiol and that of treatment with tibolone in post-menopausal women with residual endometriosis. Materials and Methods: 21 women with residual pelvic endometriosis after bilateral oophorectomy with or without hysterectomy were enrolled in the study and were randomized to HRT with transdermal estradiol 50 mg twice weekly (n=10) associated with cyclic medroxyprogesterone acetate 10 mg daily in women who preserved uterus, and to treatment with tibolone 2.5 mg administered orally once a day (n=11). The duration of both treatments was scheduled to last at least 12 months. Residual endometriosis was located in the bowel wall in four patients, in the rectovaginal septum in six and deeply in the retroperitoneal pelvic space in six. All women were symptomatic before oophorectomy. Results: All the women were followed for 12 months. No patient suspended therapy because of side effects. Four patients of the estradiol group experienced moderate pelvic pain during treatment compared with only one patient in the tibolone group. One patient in the estradiol group reported severe dyspareunia. Conclusion: Although our series is very small, it seems that tibolone may be a safe hormonal treatment for post-menopausal women with residual endometriosis. Copyright (C) 1999 Elsevier Science Ireland Ltd.",
keywords = "Endometriosis, Estrogens, Menopause, Tibolone",
author = "Luigi Fedele and Stefano Bianchi and Ricciarda Raffaelli and Giovanni Zanconato",
year = "1999",
month = "8",
day = "16",
doi = "10.1016/S0378-5122(99)00032-8",
language = "English",
volume = "32",
pages = "189--193",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis

AU - Fedele, Luigi

AU - Bianchi, Stefano

AU - Raffaelli, Ricciarda

AU - Zanconato, Giovanni

PY - 1999/8/16

Y1 - 1999/8/16

N2 - Study objective: To compare the effect of HRT with transdermal estradiol and that of treatment with tibolone in post-menopausal women with residual endometriosis. Materials and Methods: 21 women with residual pelvic endometriosis after bilateral oophorectomy with or without hysterectomy were enrolled in the study and were randomized to HRT with transdermal estradiol 50 mg twice weekly (n=10) associated with cyclic medroxyprogesterone acetate 10 mg daily in women who preserved uterus, and to treatment with tibolone 2.5 mg administered orally once a day (n=11). The duration of both treatments was scheduled to last at least 12 months. Residual endometriosis was located in the bowel wall in four patients, in the rectovaginal septum in six and deeply in the retroperitoneal pelvic space in six. All women were symptomatic before oophorectomy. Results: All the women were followed for 12 months. No patient suspended therapy because of side effects. Four patients of the estradiol group experienced moderate pelvic pain during treatment compared with only one patient in the tibolone group. One patient in the estradiol group reported severe dyspareunia. Conclusion: Although our series is very small, it seems that tibolone may be a safe hormonal treatment for post-menopausal women with residual endometriosis. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - Study objective: To compare the effect of HRT with transdermal estradiol and that of treatment with tibolone in post-menopausal women with residual endometriosis. Materials and Methods: 21 women with residual pelvic endometriosis after bilateral oophorectomy with or without hysterectomy were enrolled in the study and were randomized to HRT with transdermal estradiol 50 mg twice weekly (n=10) associated with cyclic medroxyprogesterone acetate 10 mg daily in women who preserved uterus, and to treatment with tibolone 2.5 mg administered orally once a day (n=11). The duration of both treatments was scheduled to last at least 12 months. Residual endometriosis was located in the bowel wall in four patients, in the rectovaginal septum in six and deeply in the retroperitoneal pelvic space in six. All women were symptomatic before oophorectomy. Results: All the women were followed for 12 months. No patient suspended therapy because of side effects. Four patients of the estradiol group experienced moderate pelvic pain during treatment compared with only one patient in the tibolone group. One patient in the estradiol group reported severe dyspareunia. Conclusion: Although our series is very small, it seems that tibolone may be a safe hormonal treatment for post-menopausal women with residual endometriosis. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Endometriosis

KW - Estrogens

KW - Menopause

KW - Tibolone

UR - http://www.scopus.com/inward/record.url?scp=0032803777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032803777&partnerID=8YFLogxK

U2 - 10.1016/S0378-5122(99)00032-8

DO - 10.1016/S0378-5122(99)00032-8

M3 - Article

VL - 32

SP - 189

EP - 193

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 3

ER -